Aptose Biosciences (APTO)
(Delayed Data from NSDQ)
$0.92 USD
-0.02 (-2.09%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $0.90 -0.02 (-2.17%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Brokerage Reports
0 items in cart
Aptose Biosciences, Inc. [APTO]
Reports for Purchase
Showing records 121 - 140 ( 144 total )
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Back In On ''253 and Pipeline; Upgrading to Buy; Target to $8
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
1Q16 Results; Seems Moving Toward and Answer on Formulation
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
2015 Results; Working Hard to Reset ''453 Formulation; Maintain Neutral
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Near-Term Pain for ''253 Program Though Should Get Back on Track
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
3Q15 Results; Pipeline Expansion and Driving Phase Ib Forward
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - Focusing on Value Creating Catalysts for Our CoverageThis report contains brief updates on the following: ADRO, AGTC, APHB, APTO, ARGS, BLRX, CFRX, CNCE, CYTK, CYTX, IMNP, PTN, STML, T.TST. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
2Q15 Results; Waiting for Phase Ib Updates and Pipeline Developments
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
1Q15 Results; Looking to Build ''253 Momentum by Year-End; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
4Q14 Results; Awaiting Phase Ib Updates in 2015
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Execution Phase Has Begun for APTO-253; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
ASH Update Supports Phase Ib Study; Catalysts Coming in 2015
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J